Harmony Acquires ConSynance's Asset for the Treatment of Narcolepsy and other Rare Neurological Diseases
Shots:
- Harmony to receive $3.5M up front & development and regulatory milestone along with royalties & will acquire full development and commercialization rights globally- Ex- Greater China
- The acquisition of HBS-102 marks a next-generation therapy after Wakix (pitolisant). Additionally- Harmony plans to build a robust portfolio to treat patients with rare neurological diseases & continue to pursue additional assets
- In a preclinical POC study- HBS-102 (MCHR1 antagonist) showed a reduction in cataplexy events in an orexin knockout mouse model of narcolepsy. Additionally- Harmony plans to start the P-II trial
| Ref: PR Newswire | Image: Harmony Biosciences
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
